Stock Rating Upgrade
Reflecting improving fundamentals and high Appreciation Potential, the Value Trend Rating for Supernus Pharmaceuticals Inc (NASDAQ: SUPN) improved of late. SUPN’s current Value Trend Rating is C and the prior Rating was D. Details supporting this higher rating are included in our next report.
Recent Price Action
On 8/9/24, Supernus Pharmaceuticals Inc (NASDAQ: SUPN) stock increased 2.0%, closing at $32.10. However, trading volume in this advance was below average at 81% of normal. The stock has performed in line with the market over the last nine months and has risen 8.6% during the last week.
Current PriceTarget Research Rating
SUPN’s future returns on capital are forecasted to exceed the cost of capital. Accordingly, the company is expected to continue to be a Value Builder.
Supernus Pharmaceuticals has a current Value Trend Rating of C (Neutral). This VT Rating improved in recent days from D previously. The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Supernus Pharmaceuticals has a slightly negative Appreciation Score of 38 but a slightly positive Power Rating of 60, triggering the Neutral Value Trend Rating.
Be the first to comment